Catheter‐Based Renal Denervation for Resistant Hypertension: Rationale and Design of the SYMPLICITY HTN‐3 Trial
暂无分享,去创建一个
Deepak L. Bhatt | Murray Esler | S. Oparil | W. O’Neill | G. Bakris | M. Leon | R. Townsend | J. Massaro | D. Kandzari | M. Esler | P. Sobotka | M. Negoita | J. Flack | B. Katzen | K. Rocha-Singh | Suzanne Oparil | George Bakris | William W. O'Neill | Deepak L. Bhatt | John M. Flack | Raymond R. Townsend | Martin B. Leon | Manuela Negoita | Joseph M. Massaro | C. Straley | Barry T. Katzen | Krishna Rocha-Singh | David E. Kandzari | Paul A. Sobotka | Craig Straley
[1] P. Vollenweider,et al. Differential effects of hyperinsulinemia and carbohydrate metabolism on sympathetic nerve activity and muscle blood flow in humans. , 1993, The Journal of clinical investigation.
[2] H. Krum,et al. Device-Based Antihypertensive Therapy: Therapeutic Modulation of the Autonomic Nervous System , 2011, Circulation.
[3] W. Anderson,et al. Assessment of human sympathetic nervous system activity from measurements of norepinephrine turnover. , 1988, Hypertension.
[4] Daniel W. Jones,et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. , 2008, Circulation.
[5] H. Krum,et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial , 2010, The Lancet.
[6] W. Kirkendall,et al. Surgical treatment of hypertension. , 1963, Advances in surgery.
[7] H. Krum,et al. Sympatho-renal axis in chronic disease , 2011, Clinical Research in Cardiology.
[8] G. Bakris,et al. Resistant hypertension: an overview of evaluation and treatment. , 2008, Journal of the American College of Cardiology.
[9] Michael Böhm,et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). , 2007, Journal of hypertension.
[10] Paul A. Smith,et al. Relationship between central sympathetic activity and stages of human hypertension. , 2004, American journal of hypertension.
[11] Yechiam Ostchega,et al. Hypertension awareness, treatment, and control--continued disparities in adults: United States, 2005-2006. , 2008, NCHS data brief.
[12] W. Elliott. US Trends in Prevalence, Awareness, Treatment, and Control of Hypertension, 1988-2008 , 2011 .
[13] D. Lloyd‐Jones,et al. Hypertension in adults across the age spectrum: current outcomes and control in the community. , 2005, JAMA.
[14] H. Krum,et al. Renal sympathetic-nerve ablation for uncontrolled hypertension. , 2009, The New England journal of medicine.
[15] Javed Butler,et al. The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications. , 2009, Journal of the American College of Cardiology.
[16] K. Rahn,et al. Sympathetic Nerve Activity in End-Stage Renal Disease , 2002, Circulation.
[17] W. Elliott,et al. What is the prevalence of resistant hypertension in the United States? , 2012, Current opinion in cardiology.
[18] G. Mancia,et al. The sympathetic nervous system and the metabolic syndrome. , 2007, Journal of hypertension.
[19] W. Gerth,et al. Four-Year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other artihypertensive drug classes. , 2001, Clinical therapeutics.
[20] W. J. Elliott,et al. Hypertension Awareness, Treatment, and Control — Continued Disparities in Adults: United States, 2005-2006 , 2009 .
[21] G. Dibona,et al. Translational medicine: the antihypertensive effect of renal denervation. , 2010, American journal of physiology. Regulatory, integrative and comparative physiology.
[22] Jiang He,et al. Primary prevention of hypertension: clinical and public health advisory from The National High Blood Pressure Education Program. , 2002, JAMA.
[23] K. Reynolds,et al. Global burden of hypertension: analysis of worldwide data , 2005, The Lancet.
[24] R. Collins,et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies , 2002, The Lancet.
[25] H. Krum,et al. Effect of Renal Sympathetic Denervation on Glucose Metabolism in Patients With Resistant Hypertension: A Pilot Study , 2011, Circulation.
[26] M. Castanheira,et al. Prevalence and Antimicrobial Susceptibility Profile of ESBL- and KPC-producing Enterobacteriaceae in the United States (2003 − 2008) , 2010 .
[27] V. Somers,et al. Baroreflex control of sympathetic nerve activity and heart rate in obstructive sleep apnea. , 1998, Hypertension.
[28] Symplicity Htn Investigators,et al. Catheter-Based Renal Sympathetic Denervation for Resistant Hypertension: Durability of Blood Pressure Reduction Out to 24 Months , 2011, Hypertension.
[29] Michael Böhm,et al. Renal denervation: a potential new treatment modality for polycystic ovary syndrome? , 2011, Journal of hypertension.
[30] D. Mozaffarian,et al. Heart disease and stroke statistics--2012 update: a report from the American Heart Association. , 2012, Circulation.
[31] B. Egan,et al. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. , 2010, JAMA.
[32] R. Converse,et al. Sympathetic overactivity in patients with chronic renal failure. , 1992, The New England journal of medicine.
[33] Piotr Ponikowski,et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). , 2007, European heart journal.
[34] J. Thompson,et al. Splanchnicectomy for essential hypertension; results in 1,266 cases. , 1953, Journal of the American Medical Association.
[35] H. Krum,et al. Renal denervation and hypertension. , 2011, American journal of hypertension.
[36] E. Scott,et al. Impact of Type 2 Diabetes Mellitus on Sympathetic Neural Mechanisms in Hypertension , 2003, Circulation.
[37] C. Longland,et al. Sympathectomy in the treatment of benign and malignant hypertension : A review of 76 patients , 1954, The British journal of surgery.
[38] D. Goff,et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. , 2008, Circulation.
[39] Krzysztof Bartus,et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study , 2009, The Lancet.
[40] P. Korner,et al. Total, and organ-specific, noradrenaline plasma kinetics in essential hypertension. , 1984, Clinical and experimental hypertension. Part A, Theory and practice.
[41] Bernard J. Gersh,et al. Treatment of Hypertension in the Prevention and Management of Ischemic Heart Disease: A Scientific Statement From the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention , 2007, Circulation.